JP2013532126A - クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法 - Google Patents

クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法 Download PDF

Info

Publication number
JP2013532126A
JP2013532126A JP2013510087A JP2013510087A JP2013532126A JP 2013532126 A JP2013532126 A JP 2013532126A JP 2013510087 A JP2013510087 A JP 2013510087A JP 2013510087 A JP2013510087 A JP 2013510087A JP 2013532126 A JP2013532126 A JP 2013532126A
Authority
JP
Japan
Prior art keywords
chlorotoxin
modified
peptide
modified chlorotoxin
imaging
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013510087A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013532126A5 (https=
Inventor
オルソン、ジェームズ・エム．
Original Assignee
フレッド ハッチンソン キャンサー リサーチ センター
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フレッド ハッチンソン キャンサー リサーチ センター filed Critical フレッド ハッチンソン キャンサー リサーチ センター
Publication of JP2013532126A publication Critical patent/JP2013532126A/ja
Publication of JP2013532126A5 publication Critical patent/JP2013532126A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Insects & Arthropods (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2013510087A 2010-05-11 2011-02-04 クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法 Pending JP2013532126A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33355610P 2010-05-11 2010-05-11
US61/333,556 2010-05-11
PCT/US2011/023797 WO2011142858A2 (en) 2010-05-11 2011-02-04 Chlorotoxin variants, conjugates, and methods for their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017023098A Division JP6553105B2 (ja) 2010-05-11 2017-02-10 クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法

Publications (2)

Publication Number Publication Date
JP2013532126A true JP2013532126A (ja) 2013-08-15
JP2013532126A5 JP2013532126A5 (https=) 2014-05-01

Family

ID=44914898

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013510087A Pending JP2013532126A (ja) 2010-05-11 2011-02-04 クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法
JP2017023098A Expired - Fee Related JP6553105B2 (ja) 2010-05-11 2017-02-10 クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017023098A Expired - Fee Related JP6553105B2 (ja) 2010-05-11 2017-02-10 クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法

Country Status (10)

Country Link
US (2) US9944683B2 (https=)
EP (2) EP3165533B1 (https=)
JP (2) JP2013532126A (https=)
KR (1) KR101972173B1 (https=)
CN (2) CN103097403B (https=)
AU (1) AU2011253424B2 (https=)
CA (1) CA2799169C (https=)
ES (2) ES2601182T3 (https=)
IL (1) IL222930B (https=)
WO (1) WO2011142858A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013518905A (ja) * 2010-02-04 2013-05-23 モルフォテック， インコーポレイテッド クロロトキシンポリペプチドおよびコンジュゲートならびにその使用
JP2016534147A (ja) * 2013-09-17 2016-11-04 ブレイズ バイオサイエンス， インコーポレイテッド クロロトキシンコンジュゲート及びその使用方法
CN109963597A (zh) * 2016-11-10 2019-07-02 北京普罗吉生物科技发展有限公司 聚乙二醇化血管内皮抑制素类似物及其应用
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE502048T1 (de) 2005-04-22 2011-04-15 Univ Washington Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
ES2658852T3 (es) 2008-01-18 2018-03-12 Visen Medical, Inc. Agentes de imaginología fluorescentes
US8227439B2 (en) 2008-05-15 2012-07-24 Morphotek, Inc. Treatment of metastatic tumors
JP2013532126A (ja) 2010-05-11 2013-08-15 フレッド ハッチンソン キャンサー リサーチ センター クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法
CN102688496B (zh) * 2012-01-15 2013-12-11 河南科技大学 一种ctx介导的靶向纳米载体及纳米载药体系
CN105008393A (zh) 2012-12-10 2015-10-28 弗莱德哈钦森癌症研究中心 用于筛选的方法
US9784730B2 (en) 2013-03-21 2017-10-10 University Of Washington Through Its Center For Commercialization Nanoparticle for targeting brain tumors and delivery of O6-benzylguanine
US11559580B1 (en) * 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
CN106573054B (zh) * 2014-06-02 2021-04-13 乐天医药生技股份有限公司 酞菁探针及其用途
WO2016210376A2 (en) * 2015-06-26 2016-12-29 Fred Hutchinson Cancer Research Center Therapeutic peptides and methods of use thereof
US11090358B2 (en) 2015-09-09 2021-08-17 Fred Hutchinson Cancer Research Center Cartilage-homing peptides
HK1259021A1 (zh) * 2015-10-07 2019-11-22 基因泰克公司 用於預測治療劑-聚合物綴合物的玻璃體半衰期的系統和方法
US20190161523A1 (en) 2016-04-12 2019-05-30 Blaze Bioscience, Inc. Methods of treatment using chlorotoxin conjugates
EP3529315B1 (en) * 2016-10-21 2024-12-04 Da Zen Theranostics, Inc Near infrared (nir) dye cancer drug conjugated to a statin
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
AU2018210157B2 (en) 2017-01-18 2022-10-06 Fred Hutchinson Cancer Center Peptide compositions and methods of use thereof for disrupting TEAD interactions
EP3595699A4 (en) 2017-03-16 2020-12-23 Blaze Bioscience, Inc. PEPTIDIC CONJUGATES OF CARTILAGE ECOTROPISM AND THEIR METHODS OF USE
AU2018283161A1 (en) 2017-06-15 2020-01-02 Blaze Bioscience, Inc. Renal-homing peptide conjugates and methods of use thereof
EP3681540A4 (en) 2017-09-15 2021-05-19 Eisai, Inc. CHLOROTOXIN AGENT AND USES THEREOF
EP3727146A4 (en) 2017-12-19 2021-10-06 Blaze Bioscience, Inc. TUMOR HOMING AND CELL-PENETANT PEPTIDE IMMUNO-ONCOLOGY AGENT COMPLEX AND METHOD OF USE
EP4076500A4 (en) * 2019-12-19 2023-12-27 Blaze Bioscience, Inc. METHOD FOR TREATING VASCULAR LESIONS AND MALFORMATIONS
EP4271702B1 (en) 2020-12-30 2024-11-06 VRG Therapeutics Zrt. Chlorotoxin derivatives and use thereof

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009502A1 (en) * 1998-08-12 2000-02-24 Daiichi Pure Chemicals Co., Ltd. Fluorescent labelling reagents
WO2006115633A2 (en) * 2005-04-22 2006-11-02 University Of Washington Cyanine-chlorotoxin conjugate and method for intra-operative fluorescent visualization of cancer
JP2008538506A (ja) * 2005-04-22 2008-10-30 アムジエン・インコーポレーテツド 延長された血液半減期を有するトキシンペプチド
US20090004105A1 (en) * 2007-06-27 2009-01-01 Zhen Cheng Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin
WO2009114776A2 (en) * 2008-03-14 2009-09-17 Visen Medical, Inc. Integrin targeting agents and methods of using same
WO2009133362A2 (en) * 2008-04-29 2009-11-05 Cambridge Enterprise Limited Agents for detecting and imaging cell death
WO2009140599A1 (en) * 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
JP2009280567A (ja) * 2008-02-28 2009-12-03 Kyoto Univ 多点リン酸化ペプチド（タンパク）認識化合物、それを用いる検出方法
JP2009300110A (ja) * 2008-06-10 2009-12-24 Olympus Corp 移植細胞の光学的検出方法又はイメージング方法
WO2010029760A1 (en) * 2008-09-12 2010-03-18 Nitto Denko Corporation Imaging agents of fibrotic diseases
JP2010085108A (ja) * 2008-09-29 2010-04-15 Nano Factory:Kk 生体光イメージング用プローブ
WO2011097533A1 (en) * 2010-02-04 2011-08-11 Transmolecular, Inc. Chlorotoxin polypeptides and conjugates and uses thereof

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444744A (en) 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
DE3407582A1 (de) 1984-03-01 1985-09-05 Dornier System Gmbh, 7990 Friedrichshafen Schaltungsanordnung fuer einen regelkreis
EP0282581A4 (en) 1986-09-19 1988-11-02 Scripps Clinic Res Monoclonal paratopic molecule directed to human ganglioside gd2.
US5591829A (en) 1987-05-29 1997-01-07 Matsushita; Shuzo Antibodies modified with toxic substance
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
US5051364A (en) 1989-02-16 1991-09-24 The Salk Institute For Biological Studies Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies
DE3909799A1 (de) 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
EP0491007B1 (en) 1989-09-08 1996-03-13 The Johns Hopkins University Structural alterations of the egf receptor gene in human gliomas
US5223253A (en) 1989-09-28 1993-06-29 American Home Products Corporation Bovine vaccine compositions and method for preventing trichomonas infections using same
GB2250993B (en) 1990-11-21 1995-02-15 Inst Nat Sante Rech Med Stromelysin-3 and its application in the diagnosis and treatment of malignant breast cancer
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
MX9205293A (es) 1991-09-20 1993-05-01 Syntex Sinergen Neuroscience J Factores neurotrofico derivado del glial
US5314992A (en) 1991-11-25 1994-05-24 Trustees Of Dartmouth College Lipocortin-1 receptor protein and its uses
EP0642353A1 (en) 1992-05-14 1995-03-15 Oncologix, Inc. Treatment of vascular leakage syndrome and collagenase induced disease by administration of matrix metalloproteinase inhibitors
UA29466C2 (uk) 1993-01-14 2000-11-15 Канзер Рісерч Кампейн Технолоджі, Лтд Фармацевтична композиція з антипухлинною активністю
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5688773A (en) 1994-08-17 1997-11-18 The General Hospital Corporation Method of selectively destroying neoplastic cells
US5985822A (en) 1994-12-09 1999-11-16 The Scripps Research Institute Inhibition of glial cell proliferation with N-CAM homophilic peptides
US5756340A (en) 1995-05-08 1998-05-26 The Regents Of The University Of California Insect control with multiple toxins
JP3809502B2 (ja) 1995-05-30 2006-08-16 二郎 有川 ハンタウィルス抗原蛋白質およびモノクローナル抗体
JPH0971599A (ja) 1995-09-06 1997-03-18 Nippon Seibutsu Kagaku Kenkyusho 鶏貧血ウイルス（ｃａｖ）感染鶏血清と高い反応性を示すポリペプチド及びこのポリペプチドに対する抗体、鶏貧血ウイルス感染の診断法及びワクチン
US6667156B2 (en) 1995-12-27 2003-12-23 Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors
US5905027A (en) 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
US6130101A (en) 1997-09-23 2000-10-10 Molecular Probes, Inc. Sulfonated xanthene derivatives
AU748250B2 (en) 1997-12-05 2002-05-30 Kyogo Itoh Tumor antigen peptide derivatives
GB9809776D0 (en) 1998-05-07 1998-07-08 Nycomed Imaging As Method
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US6214986B1 (en) 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
SE9901387D0 (sv) 1999-04-19 1999-04-19 Astra Ab New pharmaceutical foromaulations
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6767635B1 (en) 1999-09-14 2004-07-27 Biomedical Apherese Systeme Gmbh Magnetic nanoparticles having biochemical activity, method for the production thereof and their use
AU4305101A (en) 1999-11-22 2001-06-04 Research Foundation Of The State University Of New York, The Magnetic nanoparticles for selective therapy
DE10020376A1 (de) 2000-04-26 2001-11-08 Inst Zelltechnologie E V Dynamische Marker
CA2427858A1 (en) * 2000-11-03 2002-05-10 University Of Vermont And State Agricultural College Compositions for inhibiting grb7
US20020077921A1 (en) 2000-12-15 2002-06-20 Paul-David Morrison Method and apparatus for an interactive catalog
WO2002069896A2 (en) 2001-03-01 2002-09-12 Northwest Hospital Connexin enhances chemotherapy-induced apoptosis in human cancer cells inhibiting tumor cell proliferation
WO2003008583A2 (en) 2001-03-02 2003-01-30 Sagres Discovery Novel compositions and methods for cancer
WO2003000203A2 (en) 2001-06-26 2003-01-03 Uab Research Foundation Chlorotoxin inhibition of cell invasion, cancer metastasis, angiogenesis and tissue remodeling
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US6972326B2 (en) 2001-12-03 2005-12-06 Molecular Probes, Inc. Labeling of immobilized proteins using dipyrrometheneboron difluoride dyes
WO2003066663A2 (en) 2002-02-04 2003-08-14 Auburn University Peptides for recognition and targeting of glial cell tumors
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
WO2003101474A1 (en) * 2002-05-31 2003-12-11 Transmolecular, Inc. Combination chemotherapy with chlorotoxin
US20060088899A1 (en) 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
US7560160B2 (en) 2002-11-25 2009-07-14 Materials Modification, Inc. Multifunctional particulate material, fluid, and composition
US20040101822A1 (en) 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
DE10328251A1 (de) 2003-06-24 2005-01-13 Toximed Gmbh Pharmazeutischer Wirkstoff
WO2005053611A2 (en) 2003-11-26 2005-06-16 Transmolecular, Inc. Treatment of phosphatidylinositol phospholipid disorders
US20080153746A1 (en) * 2004-04-06 2008-06-26 Transmolecular, Inc. Diagnosis and Treatment of Myeloid and Lymphoid Cell Cancers
DE602005019728D1 (de) 2004-04-06 2010-04-15 Transmolecular Inc Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat
CA2565701A1 (en) 2004-05-06 2005-11-17 Jonathan M. Barasch Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
JP2008507280A (ja) 2004-07-21 2008-03-13 アンブレツクス・インコーポレイテツド 非天然コードアミノ酸を用いた生合成ポリペプチド
GB0422901D0 (en) 2004-10-14 2004-11-17 Ares Trading Sa Lipocalin protein
KR100681763B1 (ko) 2005-02-28 2007-02-15 재단법인 목암생명공학연구소 인간 리포칼린 2를 유효성분으로 포함하는 암 전이 억제용약학적 조성물, 이를 이용한 암 전이 억제 방법
GB0504767D0 (en) 2005-03-08 2005-04-13 Ares Trading Sa Lipocalin protein
US7462446B2 (en) 2005-03-18 2008-12-09 University Of Washington Magnetic nanoparticle compositions and methods
US20070037232A1 (en) 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
EP1871911A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
WO2006110582A1 (en) 2005-04-08 2006-10-19 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
MX2008002149A (es) 2005-08-18 2008-04-22 Ambrx Inc Composiciones de arnt y sus usos.
EP2147927A3 (en) 2006-03-31 2010-09-01 Transmolecular, Inc. Use of 131i-tm-601 for the diagnosis and treatment of gliomas
EP2029157A4 (en) 2006-05-19 2009-11-18 Georgia Tech Res Inst ABC TRANSPORTERLIGAND
CN101003788A (zh) 2006-09-21 2007-07-25 武汉大学 一种蝎抗肿瘤转移肽及其制备方法和应用
CN100564517C (zh) 2006-09-21 2009-12-02 武汉大学 一种蝎抗神经胶质瘤肽及其制备方法和应用
PE20081140A1 (es) * 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
CA2696303A1 (en) 2007-08-07 2009-02-12 Transmolecular, Inc. Chlorotoxins as drug carriers
US20110283260A1 (en) 2007-08-31 2011-11-17 Iosemantics, Llc Quality assurance tools for use with source code and a semantic model
EP2211913A4 (en) 2007-10-12 2010-12-22 Transmolecular Inc SYSTEMIC ADMINISTRATION OF CHLOROTOXIN AGENTS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
US7904868B2 (en) 2007-10-17 2011-03-08 International Business Machines Corporation Structures including means for lateral current carrying capability improvement in semiconductor devices
US20090123946A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090123970A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Glycosylated mammalian ngal and use thereof
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090124022A1 (en) 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US20090269777A1 (en) 2007-10-19 2009-10-29 Abbott Laboratories Immunoassays and kits for the detection of ngal
CA2702611A1 (en) 2007-10-19 2009-04-23 Abbott Laboratories Immunoassays and kits for the detection of ngal
US20090176274A1 (en) 2007-10-19 2009-07-09 Abbott Laboratories Glycosylated mammalian ngal and use thereof
CN101910845A (zh) 2007-11-15 2010-12-08 比奥波托诊断股份公司 个体分子形式的生物标志的诊断用途
ES2658852T3 (es) * 2008-01-18 2018-03-12 Visen Medical, Inc. Agentes de imaginología fluorescentes
US9308239B2 (en) 2008-02-26 2016-04-12 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
CN102056617A (zh) 2008-03-20 2011-05-11 特兰斯莫莱库拉公司 血管生成的抑制
CN101270158B (zh) 2008-04-30 2010-12-22 武汉大学 一种靶向抗神经胶质瘤蛋白及制备方法和用途
JP5711118B2 (ja) 2008-06-24 2015-04-30 テクニッシュ ウニヴェルジテート ミュンヘン 所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン
US20100098637A1 (en) * 2008-09-23 2010-04-22 The Regents Of The University Of Michigan Dye-loaded nanoparticle
CN101381405B (zh) 2008-09-24 2011-07-27 武汉摩尔生物科技有限公司 基因工程肿瘤靶向kct-w1多肽及制备方法和用途
US20100105150A1 (en) 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
CN102791827B (zh) 2009-11-09 2016-11-16 华盛顿大学商业化中心 官能化发色聚合物点及其生物共轭体
CN101921769B (zh) 2010-01-11 2012-07-25 山西大学 一种重组腺病毒及其制备方法和应用
WO2011094671A2 (en) 2010-01-29 2011-08-04 The Uab Research Foundation N-terminally conjugated polypeptides for targeted therapy and diagnosis
CN101824084A (zh) 2010-04-08 2010-09-08 山西大学 靶向性抗胶质瘤蛋白质及其应用
JP2013532126A (ja) 2010-05-11 2013-08-15 フレッド ハッチンソン キャンサー リサーチ センター クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法
NZ606584A (en) 2010-08-16 2014-10-31 Pieris Ag Binding proteins for hepcidin
CN105008393A (zh) 2012-12-10 2015-10-28 弗莱德哈钦森癌症研究中心 用于筛选的方法
EP3442555A4 (en) * 2016-04-15 2020-04-01 Blaze Bioscience, Inc. METHOD FOR TREATING BREAST CANCER
WO2017181149A1 (en) * 2016-04-15 2017-10-19 Blaze Bioscience, Inc. Methods of treating breast cancer

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009502A1 (en) * 1998-08-12 2000-02-24 Daiichi Pure Chemicals Co., Ltd. Fluorescent labelling reagents
WO2006115633A2 (en) * 2005-04-22 2006-11-02 University Of Washington Cyanine-chlorotoxin conjugate and method for intra-operative fluorescent visualization of cancer
JP2008538506A (ja) * 2005-04-22 2008-10-30 アムジエン・インコーポレーテツド 延長された血液半減期を有するトキシンペプチド
US20090004105A1 (en) * 2007-06-27 2009-01-01 Zhen Cheng Molecular imaging of matrix metalloproteinase expression using labeled chlorotoxin
JP2009280567A (ja) * 2008-02-28 2009-12-03 Kyoto Univ 多点リン酸化ペプチド（タンパク）認識化合物、それを用いる検出方法
WO2009114776A2 (en) * 2008-03-14 2009-09-17 Visen Medical, Inc. Integrin targeting agents and methods of using same
WO2009133362A2 (en) * 2008-04-29 2009-11-05 Cambridge Enterprise Limited Agents for detecting and imaging cell death
WO2009140599A1 (en) * 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
JP2009300110A (ja) * 2008-06-10 2009-12-24 Olympus Corp 移植細胞の光学的検出方法又はイメージング方法
WO2010029760A1 (en) * 2008-09-12 2010-03-18 Nitto Denko Corporation Imaging agents of fibrotic diseases
JP2010085108A (ja) * 2008-09-29 2010-04-15 Nano Factory:Kk 生体光イメージング用プローブ
WO2011097533A1 (en) * 2010-02-04 2011-08-11 Transmolecular, Inc. Chlorotoxin polypeptides and conjugates and uses thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6015011611; Ｃａｎｃｅｒ　Ｒｅｓ．，　２００７，　６７（１４），　ｐｐ．６８８２-６８８８ *
JPN6015011614; Ｎａｎｏ　Ｌｅｔｔ．，　２００５，　５（６），　ｐｐ．１００３-１００８ *
JPN6015011617; Ｃａｎｃｅｒ　Ｒｅｓ．，　２００９，　６９（１５），　ｐｐ．６２００-６２０７ *
JPN6015011620; Ｊ．　Ｃｈｒｏｍａｔｏｇｒ．　Ｂ，　２００４，　８０３（１），　ｐｐ．６７-７３ *
JPN6015011623; ＦＥＢＳ　Ｌｅｔｔ．，　１９９８，　４４１（３），　ＰＰ．３８７-３９１ *
JPN6016038544; Ｊ． Ｍｅｄ． Ｉｎｖｅｓｔ．， ２００６， ５３（１-２）， ｐｐ．５２-６０ *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015212307A (ja) * 2010-02-04 2015-11-26 モルフォテック， インコーポレイテッド クロロトキシンポリペプチドおよびコンジュゲートならびにその使用
JP2017031205A (ja) * 2010-02-04 2017-02-09 モルフォテック， インコーポレイテッド クロロトキシンポリペプチドおよびコンジュゲートならびにその使用
US10183975B2 (en) 2010-02-04 2019-01-22 Morphotek, Inc. Chlorotoxin polypeptides and conjugates and uses thereof
JP2013518905A (ja) * 2010-02-04 2013-05-23 モルフォテック， インコーポレイテッド クロロトキシンポリペプチドおよびコンジュゲートならびにその使用
JP6994011B2 (ja) 2013-09-17 2022-02-03 ブレイズ バイオサイエンス， インコーポレイテッド クロロトキシンコンジュゲート及びその使用方法
JP2016534147A (ja) * 2013-09-17 2016-11-04 ブレイズ バイオサイエンス， インコーポレイテッド クロロトキシンコンジュゲート及びその使用方法
JP2020019779A (ja) * 2013-09-17 2020-02-06 ブレイズ バイオサイエンス， インコーポレイテッド クロロトキシンコンジュゲート及びその使用方法
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
JP2019535700A (ja) * 2016-11-10 2019-12-12 ベイジン プロトゲン リミテッドＢｅｉｊｉｎｇ Ｐｒｏｔｇｅｎ Ｌｔｄ． ペグ化エンドスタチン類似体およびその適用
CN109963597B (zh) * 2016-11-10 2022-08-26 北京普罗吉生物科技发展有限公司 聚乙二醇化血管内皮抑制素类似物及其应用
JP7140454B2 (ja) 2016-11-10 2022-09-21 ベイジン プロトゲン リミテッド ペグ化エンドスタチン類似体およびその適用
CN115721730A (zh) * 2016-11-10 2023-03-03 北京普罗吉生物科技发展有限公司 聚乙二醇化血管内皮抑制素类似物及其应用
CN109963597A (zh) * 2016-11-10 2019-07-02 北京普罗吉生物科技发展有限公司 聚乙二醇化血管内皮抑制素类似物及其应用

Also Published As

Publication number Publication date
EP2569330A4 (en) 2013-11-13
CN106957356B (zh) 2021-05-25
US20130195760A1 (en) 2013-08-01
IL222930B (en) 2019-01-31
US10822381B2 (en) 2020-11-03
CA2799169C (en) 2019-07-23
WO2011142858A9 (en) 2012-03-22
EP3165533A1 (en) 2017-05-10
US9944683B2 (en) 2018-04-17
KR20130113938A (ko) 2013-10-16
CA2799169A1 (en) 2011-11-17
WO2011142858A3 (en) 2012-01-05
JP6553105B2 (ja) 2019-07-31
WO2011142858A2 (en) 2011-11-17
IL222930A0 (en) 2012-12-31
AU2011253424A1 (en) 2012-12-20
CN103097403A (zh) 2013-05-08
ES2601182T3 (es) 2017-02-14
CN103097403B (zh) 2017-04-19
EP3165533B1 (en) 2020-04-08
CN106957356A (zh) 2017-07-18
AU2011253424B2 (en) 2016-02-04
EP2569330B1 (en) 2016-09-28
ES2811065T3 (es) 2021-03-10
KR101972173B1 (ko) 2019-04-24
US20180194818A1 (en) 2018-07-12
JP2017137316A (ja) 2017-08-10
EP2569330A2 (en) 2013-03-20

Similar Documents

Publication Publication Date Title
JP6553105B2 (ja) クロロトキシン変異体、コンジュゲート、およびそれらを使用する方法
US12465660B2 (en) Compositions and methods for cancer imaging and radiotherapy
CN116804049A (zh) 铁蛋白示踪多肽缀合物及其用途
CN117777237A (zh) 一种靶向bcma的多肽及其应用
AU2013204119B2 (en) Chlorotoxin variants, conjugates, and methods for their use
JP2020531478A (ja) 新規ペプチド系癌造影剤
US20250263439A1 (en) Heterodimeric peptide reagents and methods
US20250073355A1 (en) Cd44-binding peptide reagents and methods
CN116217664A (zh) 靶向mHSP90的多肽、分子探针及应用
Ablack Viral nanoparticles: Intravital imaging of human prostate cancer using viral nanoparticles targeted to gastrin-releasing peptide receptors (small 12/2011)
Cupka Development of an αᵥβ₆-Binding Peptide for In Vivo Applications: Modulation of Serum Stability and Biodistribution
EA042953B1 (ru) Композиции и способы для визуализации и лучевой терапии рака

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140312

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150623

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150824

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160415

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160719

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20161011